Advertisement

Loading...

Transcenta Holding Limited

6628.HKHKSE
Healthcare
Biotechnology
HK$2.94
HK$0.20(7.30%)
Hong Kong Market is Open • 11:48

Transcenta Holding Limited Fundamental Analysis

Transcenta Holding Limited (6628.HK) shows weak financial fundamentals with a PE ratio of -5.65, profit margin of -31.04%, and ROE of -27.44%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-1.44

Areas of Concern

ROE-27.44%
Operating Margin-30.67%
Cash Position3.78%
Current Ratio0.49
We analyze 6628.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2920.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2920.6/100

We analyze 6628.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

6628.HK struggles to generate sufficient returns from assets.

ROA > 10%
-18.11%

Valuation Score

Excellent

6628.HK trades at attractive valuation levels.

PE < 25
-5.65
PEG Ratio < 2
-1.44

Growth Score

Weak

6628.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

6628.HK shows balanced financial health with some risks.

Debt/Equity < 1
0.32
Current Ratio > 1
0.49

Profitability Score

Weak

6628.HK struggles to sustain strong margins.

ROE > 15%
-2744.34%
Net Margin ≥ 15%
-31.04%
Positive Free Cash Flow
No

Key Financial Metrics

Is 6628.HK Expensive or Cheap?

P/E Ratio

6628.HK trades at -5.65 times earnings. This suggests potential undervaluation.

-5.65

PEG Ratio

When adjusting for growth, 6628.HK's PEG of -1.44 indicates potential undervaluation.

-1.44

Price to Book

The market values Transcenta Holding Limited at 1.63 times its book value. This may indicate undervaluation.

1.63

EV/EBITDA

Enterprise value stands at -6.22 times EBITDA. This is generally considered low.

-6.22

How Well Does 6628.HK Make Money?

Net Profit Margin

For every $100 in sales, Transcenta Holding Limited keeps $-31.04 as profit after all expenses.

-31.04%

Operating Margin

Core operations generate -30.67 in profit for every $100 in revenue, before interest and taxes.

-30.67%

ROE

Management delivers $-27.44 in profit for every $100 of shareholder equity.

-27.44%

ROA

Transcenta Holding Limited generates $-18.11 in profit for every $100 in assets, demonstrating efficient asset deployment.

-18.11%

Following the Money - Real Cash Generation

Operating Cash Flow

Transcenta Holding Limited generates limited operating cash flow of $-128.25M, signaling weaker underlying cash strength.

$-128.25M

Free Cash Flow

Transcenta Holding Limited generates weak or negative free cash flow of $-133.15M, restricting financial flexibility.

$-133.15M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

6628.HK converts -11.50% of its market value into free cash.

-11.50%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.44

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.63

vs 25 benchmark

P/S Ratio

Price to sales ratio

183.03

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.32

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.49

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.27

vs 25 benchmark

ROA

Return on assets percentage

-0.18

vs 25 benchmark

ROCE

Return on capital employed

-0.25

vs 25 benchmark

How 6628.HK Stacks Against Its Sector Peers

Metric6628.HK ValueSector AveragePerformance
P/E Ratio-5.6528.31 Better (Cheaper)
ROE-27.44%699.00% Weak
Net Margin-3103.72%-130884.00% (disorted) Weak
Debt/Equity0.320.34 Neutral
Current Ratio0.492775.16 Weak Liquidity
ROA-18.11%-14469.00% (disorted) Weak

6628.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Transcenta Holding Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ